참고문헌
- Beer M, Montari M, Gerhard J, et al (2012). Profiling gastrinreleasing peptide receptor in prostate tissues: Clinical implications and molecular correlates. Prostate, 72, 318-22 https://doi.org/10.1002/pros.21434
- Bele T (2012). Treating cancer with vaccine. Web Med Central Immunopathol, 3, 3267.
- Boehm T, Folkman J, Browder T, et al (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390, 404-7. https://doi.org/10.1038/37126
- Butterfield LH (2007). Recent advances in immunotherapy for hepatocellular cancer. Swiss Med Wkly, 137, 83-90.
- Donnelly JJ, Ulmer JB, Shiver JW, et al (1997). DNA vaccines. Ann Rev Immunol, 15, 617-48. https://doi.org/10.1146/annurev.immunol.15.1.617
- Egloff AM, Davis AG, Shuai YL, et al (2012). Gastrin-releasing expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study. Respiratory Research, 13, 9. https://doi.org/10.1186/1465-9921-13-9
- Fang F, Lu Y, Ouyang K, et al (2009). Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo. Clin Vaccine Immunol, 16, 1033-39. https://doi.org/10.1128/CVI.00046-09
- Folkman F (1996). Fighting cancer by attacking its blood supply. Sci Am, 275, 150-4. https://doi.org/10.1038/scientificamerican0996-150
- Folkman F (1997). Antiangiogenic Therapy. In Principles and Practice of Oncology. 9th Ed DeVita V T, Hellman S, Rosenberg SA, Lippincott Williams & Wilkins (LWW) Philadelphia: Lippincott- Raven) pp 3075-85 Number 978-2.
- Gordan JD, Simon MC (2007). Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev, 17, 71-77. https://doi.org/10.1016/j.gde.2006.12.006
- Greten TF, Papendorf F, Bleck JS, et al (2006). Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer, 92, 1862-8.
- Gruber M, Simon MC (2006). Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Curr Opin Hematol, 13, 169-74. https://doi.org/10.1097/01.moh.0000219663.88409.35
- Hohla F, Schally AV (2010). Targeting gastrin releasing receptors New options for the therapy and diagnosis of cancer. Cell Cycle, 9, 1738-41. https://doi.org/10.4161/cc.9.9.11347
- Huang J, Soffer SZ, Kim ES, et al (2004). Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res, 2, 36-42.
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69. https://doi.org/10.3322/caac.20107
- Kang J, Ishola TA, Baregamian N, et al (2007). Chung, Bombesin induces angiogenesis and neuroblastoma growth. Cancer Lett, 253, 273-81. https://doi.org/10.1016/j.canlet.2007.02.007
- Kreisle RA, Ershler WB (1988). Investigation of tumor angiogenesis in an id mouse model: role of host-tumor interactions. J Natl Can Inst, 80, 849-54. https://doi.org/10.1093/jnci/80.11.849
-
Lee S, Qiao JB, Pritha P, et al (2013). Integrin
$\beta{1}$ critical fro gastrin-releasing peptide receptor-mediated neuroblastoma cell migration and invasion. Surgery, 154, 369-75. https://doi.org/10.1016/j.surg.2013.04.067 - Lee SY, Kang TH, Knoff J, et al (2013). Enhanced anticancer immunotherapy with a DNA vaccine by depleting platelets. J Immunother Can, 1, 222. https://doi.org/10.1186/2051-1426-1-S1-P222
- Levine L, Lucci JA, Pazdrak B, et al (2003). Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res, 63, 3495-502.
- Lu Y, Ouyang K, Fang J, et al (2009). Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope. Vaccine, 27, 5418-511.
- Luigi A and Ciliberto G (2011). Emerging cancer vaccines: The promise of genetic vectors. Cancers, 3, 3687- 713. https://doi.org/10.3390/cancers3033687
- Martins FF, Contu PC, Meurer L, et al (2013). Expression of gastrin-releasing peptide receptor in epidermoid carcinoma of anal canal. Appl Immunohistochem Mol Morphol.
- Matejuk A, Leng Q, Chou ST, et al (2011). Vaccines targeting the neovasculature of tumors. Vasc Cell, 3, 7. https://doi.org/10.1186/2045-824X-3-7
- Ni CS, Zhao XL, Sun T, et al (2012). Role of gastrin-releasing peptide in breast cancer metastasis. Human Pathol, 12, 2342-47.
- Ozturk M and Oters S (2011). Molecular approach to treatment of hepatocellular carcinoma: New hope for therapeutic targets. J Exper Integr Med, 1, 83-4.
- Pirtha P, Qiao JB, Kim KW, et al (2013). Targeting gastrin-releasing peptide suppresses neuroblastoma progression via upregulation of PTEN signaling. PLoSONE, 8, 72570 https://doi.org/10.1371/journal.pone.0072570
- Ray K (2013). The promise of new approaches in the management of hepatocellular carcinoma adding to the toolbox? Nat Rev Gastroenterol Hepathol, 10.
- Rinaldi M, Lurescia S, Fioretti D, et al (2009). Strategies for successful vaccination against hepatocellular carcinoma. Int J Immunopathol Pharmacol, 22, 269-77.
- Rosen LS (2009). Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control, 9, 36-44.
- Wu G, Guo W, Ouyan K, et al (2008). A novel vaccine targeting gastrinreleasing peptide: efficient inhibition of breast cancer growth in vivo. Endocr Relat Cancer, 15, 149-59. https://doi.org/10.1677/ERC-07-0224
- Yankai Z, Rong Y, Yi L, Wentao L, et al (2006). Ten tandem repeats of beta-hCG 109-118 enhance immunogenicity and anti-tumor effects of betahCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Biochem Biophys Res Commun, 345, 1365-71. https://doi.org/10.1016/j.bbrc.2006.05.022
- Zhu XA, Duda DG, Sahani DV, et al (2011). HCC and angiogenesis: Possible targets and future direction. Nat Rev Clin Oncol, 8, 292-301. https://doi.org/10.1038/nrclinonc.2011.30
피인용 문헌
- Solanum Nigrum Polysaccharide (SNL) Extract Effects in Transplanted Tumor-bearing Mice - Erythrocyte Membrane Fluidity and Blocking of Functions vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10469